Sensei Biotherapeutics Inc
SNSE6.530USD
+6.204+1903.07%
Close 06/17, 16:00（ET）Quotes delayed by 15 min
164.61MMarket Cap
LossP/E TTM
More Details of Sensei Biotherapeutics Inc Company
Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
Company Info
Ticker SymbolSNSE
Company nameSensei Biotherapeutics Inc
IPO dateFeb 04, 2021
Founded at2017
CEOMr. John K. Celebi
Number of employees14
Security typeOrdinary Share
Fiscal year-endFeb 04
Address1405 Research Blvd, Suite 125
CityROCKVILLE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code20850
Phone12402438000
Websitehttps://www.senseibio.com/
Ticker SymbolSNSE
IPO dateFeb 04, 2021
Founded at2017
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas Gregory (Tom) Ricks
Mr. Thomas Gregory (Tom) Ricks
Independent Director
Independent Director
17.27K
+1.74%
Mr. Bob Holmen
Mr. Bob Holmen
Independent Director
Independent Director
1.28K
+21.10%
Mr. William R. (Bill) Ringo
Mr. William R. (Bill) Ringo
Independent Chairman of the Board
Independent Chairman of the Board
1.17K
+46.62%
Mr. Edward van Der Horst, Ph.D.
Mr. Edward van Der Horst, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. John K. Celebi
Mr. John K. Celebi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. James Peyer, Ph.D.
Dr. James Peyer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Josiah Craver
Mr. Josiah Craver
Senior Vice President of Finance, Principal Financial and Accounting Officer
Senior Vice President of Finance, Principal Financial and Accounting Officer
--
--
Mr. Kristian F. Humer
Mr. Kristian F. Humer
Independent Director
Independent Director
--
--
Mr. Michael Biega
Mr. Michael Biega
Investor Relations
Investor Relations
--
--
Ms. Stephanie Krebs
Ms. Stephanie Krebs
Chief Business Officer
Chief Business Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas Gregory (Tom) Ricks
Mr. Thomas Gregory (Tom) Ricks
Independent Director
Independent Director
17.27K
+1.74%
Mr. Bob Holmen
Mr. Bob Holmen
Independent Director
Independent Director
1.28K
+21.10%
Mr. William R. (Bill) Ringo
Mr. William R. (Bill) Ringo
Independent Chairman of the Board
Independent Chairman of the Board
1.17K
+46.62%
Mr. Edward van Der Horst, Ph.D.
Mr. Edward van Der Horst, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. John K. Celebi
Mr. John K. Celebi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. James Peyer, Ph.D.
Dr. James Peyer, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
H&S Investments I, L.P.
17.56%
Cambrian BioPharma Inc
14.49%
The Vanguard Group, Inc.
2.32%
Ikarian Capital LLC
1.78%
Ricks (Thomas Gregory)
1.37%
Other
62.47%
Shareholders
Shareholders
Proportion
H&S Investments I, L.P.
17.56%
Cambrian BioPharma Inc
14.49%
The Vanguard Group, Inc.
2.32%
Ikarian Capital LLC
1.78%
Ricks (Thomas Gregory)
1.37%
Other
62.47%
Shareholder Types
Shareholders
Proportion
Corporation
1.60%
Investment Advisor/Hedge Fund
0.18%
Hedge Fund
0.13%
Individual Investor
0.11%
Venture Capital
0.06%
Investment Advisor
0.02%
Other
97.91%
Institutional Shareholding
Updated: Tue, Mar 4
Updated: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
62
10.97M
43.52%
-1.28M
2024Q4
67
10.99M
43.71%
-5.76M
2024Q3
76
10.87M
43.20%
-6.55M
2024Q2
87
10.77M
42.86%
-5.93M
2024Q1
113
11.00M
41.97%
-8.17M
2023Q4
121
11.57M
44.26%
-7.84M
2023Q3
133
11.85M
44.62%
-7.83M
2023Q2
140
13.37M
47.63%
-5.91M
2023Q1
150
17.88M
58.08%
-1.88M
2022Q4
150
17.24M
56.17%
-867.10K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
H&S Investments I, L.P.
4.43M
17.56%
--
--
Apr 15, 2024
Cambrian BioPharma Inc
3.65M
14.47%
-4.47K
-0.12%
Apr 15, 2024
The Vanguard Group, Inc.
594.45K
2.36%
-24.30K
-3.93%
Dec 31, 2024
Ikarian Capital LLC
649.96K
2.58%
-37.00
-0.01%
Dec 31, 2024
Ricks (Thomas Gregory)
339.40K
1.35%
-4.47K
-1.30%
Apr 15, 2024
Catalio Capital Management, LP
294.37K
1.17%
+294.37K
--
Dec 31, 2024
Renaissance Technologies LLC
156.80K
0.62%
-58.77K
-27.26%
Dec 31, 2024
Geode Capital Management, L.L.C.
148.89K
0.59%
-14.25K
-8.74%
Dec 31, 2024
Boothbay Fund Management, LLC
172.80K
0.69%
-37.00
-0.02%
Dec 31, 2024
Celebi (John)
56.94K
0.23%
-5.56K
-8.89%
Feb 19, 2025
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
